Comunicación
      Nº 055

IICVHAPp.gif (9537 bytes)

IndiceIndice

TAMOXIFENO Y ENDOMETRIO

Alberto de la Cruz Mera y *Alfonso Mariño Cotelo

Comentarios

[TITULO] [INTRODUCCION] [MATERIAL Y METODOS] [RESULTADOS] [ICONOGRAFIA] [ICONOGRAFIA-2] [DISCUSION] [BIBLIOGRAFIA]

DISCUSION

TITULO

BIBLIOGRAFIA

  1. Use of tamoxifen for breast cancer: Twenty-eight yeasr later. JAIYESIMI I.A. et al. J CLIN ONCOL 1995,13:513-529.

  2. Avances en oncologia 1995. DE VITA Jr V.T., HELLMAN S., ROSENBERG S.A. Ed. ESPAXS 1996, Barcelona. Pag 215-244.

  3. Tamoxifen and tumorigenicity: a predictable concern. JORDAN V.C. J NAT CANCER INST 1995,87:623-626.

  4. Malignant neoplasms of the uterine corpus in patients treated for breast carcinoma: The effects of tamoxifen. SILVA E.G., TORNOS C.S., FOLLEN-MITCHELL M. INT J GYNECOL PATHOL 1994, 13:248-258.

  5. Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the national surgical adjuvant breast and bowel project (NSABP) B-14. FISHER B. et al. J NAT CANCER INST 1994,86:527-537.

  6. The incidence of subsequent endometrial carcinoma with tamoxifen use in patients with primary breast carcinoma. KATASE K. et al. CANCER 1998,82:1698.1703.

  7. Mucinous and clear cell adenocarcinomas of the endometrium in patients receiving antiestrogens (tamoxifen) and gestagens. DALLENBACH-HELLWEG G., HAHN U. INT J GYNECOL PATHOL 1995,14:7-15.
[TITULO] [INTRODUCCION] [MATERIAL Y METODOS] [RESULTADOS] [ICONOGRAFIA] [ICONOGRAFIA-2] [DISCUSION] [BIBLIOGRAFIA]

DISCUSION

TITULO

Alberto de la Cruz Mera y *Alfonso Mariño Cotelo
Copyright © 1998. Reservados todos los derechos.